SCHEMBL8284604

SCHEMBL8284604

Cc1cc(C)c2ncccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.68
CYP1A2 P05177 1/20 0.52
CCR1 P32246 4/20 0.47
CCR8 P51685 4/20 0.47
LMNA P02545 2/20 0.44
TOP1 P11387 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HSP90AA1 P07900 2/20 0.42
NPC1 O15118 2/20 0.42
CCR5 P51681 3/20 0.42
PSMD14 O00487 2/20 0.42
COPS5 Q92905 2/20 0.42
KDM4E B2RXH2 2/20 0.41
HTT P42858 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
MMP2 P08253 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9709737 0.81 PRMT5 (0.50) PRMT5CYP1A2CCR1CCR8LMNA
SCHEMBL6636369 0.81 PRMT5 (0.50) PRMT5CYP1A2CCR1CCR8TOP1
SCHEMBL16541495 0.81 PRMT5 (0.64) PRMT5CCR1CCR8LMNATOP1
SCHEMBL6637754 0.81 PRMT5 (0.59) PRMT5CYP1A2CCR1CCR8LMNA
SCHEMBL20468597 0.81 PRMT5 (0.50) PRMT5CYP1A2CCR1CCR8LMNA
SCHEMBL20851236 0.81 PRMT5 (0.64) PRMT5CCR1CCR8LMNATOP1
SCHEMBL24117237 0.78 PRMT5 (0.60) PRMT5CCR1CCR8LMNATOP1
SCHEMBL10266505 0.78 PRMT5 (0.47) PRMT5CYP1A2CCR1CCR8TOP1
SCHEMBL14666994 0.78 PRMT5 (0.47) PRMT5CYP1A2CCR1CCR8LMNA
SCHEMBL19986174 0.77 TOP1 (0.71) PRMT5CYP1A2CCR1CCR8TOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917906-B2 Compounds that can be used in an organic electronic device MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-20230354701-A1 COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP MERCK PATENT GMBH (DE) 2023-11-02 US disclosed
US-20230234937-A1 INDENOAZANAPHTHALENES MERCK PATENT GMBH (DE) 2023-07-27 US disclosed
US-11711976-B2 Compounds with an acceptor and a donor group MERCK PATENT GMBH (DE) 2023-07-25 US disclosed
US-11690289-B2 Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-27 US disclosed
US-20210371393-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR MEDSHINE DISCOVERY INC. (CN) 2021-12-02 US disclosed
US-20210363159-A1 HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2021-11-25 US disclosed
US-20210257559-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2021-08-19 US disclosed
US-20210167296-A1 ORGANIC COMPOUND CONTAINING HETEROCYCLIC RING AND HAVING LOW LUMO PROPERTIES, AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2021-06-03 US disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
US-20170294489-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-10-12 US disclosed
US-20170244043-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-08-24 US disclosed
US-20160351817-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2016-12-01 US disclosed
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
US-7659298-B2 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting SANOFI-AVENTIS (FR) 2010-02-09 US disclosed
US-7659298-B2 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting SANOFI-AVENTIS (FR) 2010-02-09 US disclosed
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
WO-2005060959-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R PRMT5 2414/4885CYP1A2 846/4885CCR1 649/4885
US-11690289-B2 Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same LEF1, PPOX, LIMK1 PRMT5 4225/4885CYP1A2 77/4885CCR1 2802/4885
US-11711976-B2 Compounds with an acceptor and a donor group NQO1, ICMT, NUDT1 PRMT5 1230/4885CYP1A2 394/4885CCR1 2749/4885
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 PRMT5 3587/4885CYP1A2 2440/4885CCR1 14/4885
US-20210363159-A1 HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES DDT, NQO1, CYP2E1 PRMT5 1832/4885CYP1A2 11/4885CCR1 3162/4885
US-20230234937-A1 INDENOAZANAPHTHALENES NQO1, CYP2D6, SQOR PRMT5 2119/4885CYP1A2 17/4885CCR1 4652/4885
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R PRMT5 2414/4885CYP1A2 846/4885CCR1 649/4885
US-20230354701-A1 COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP NQO1, ICMT, NUDT1 PRMT5 1230/4885CYP1A2 394/4885CCR1 2749/4885
US-20210371393-A1 BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR ROCK1, ROCK2, CIT PRMT5 1340/4885CYP1A2 513/4885CCR1 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.